A new member of the atypical protein kinase C (aPKC) family, designated PKCfII, is identified in this study. The gene contains no introns and is 98% homologous with the cDNA encoding PKCf. The PKCfII coding region is frameshifted with respect to the PKCf open reading frame, resulting in expression of an aPKC regulatory domain without associated kinase activity. PKCfII mRNA is detected in various mouse tissues and an immunoreactive 45 kDa protein is present in epithelial cell cultures. PKCfII is shown to interact with the Par6 protein and functions in the development of cell polarity. HC11 epithelial cells express PKCfII and are maintained in a nondifferentiated state characterised by the absence of tight junctions and cell overgrowth. HC11 cells harbouring a PKCfII-specific RNAi, recruit ZO-1 and other tight junction markers to cell-cell boundaries and adopt a monolayer phenotype in the presence of growth factors. The data demonstrate a regulatory role for PKCfII in the maintenance of cell transformation and the development of cell polarity.
Introduction
Cell polarisation is a fundamental property of every cell type, with symmetric and/or asymmetric distribution of cellular components being essential for the development, cell division, cell migration, and maintenance of specialised compartments within cells. Atypical protein kinase (aPKC) is implicated in the development of cellular asymmetry and contributes to astrocyte migration and epithelial cell polarity (Joberty et al, 2000; Lin et al, 2000; Etienne-Manneville and Hall, 2001; Hirose et al, 2002) .
Epithelial cells are composed of distinct apical (lumenal) and basolateral domains separated by a specialised cellular structure known as the tight junction. The tight junction maintains a barrier that prevents diffusion of molecules across the epithelial cell layer (Dragsten et al, 1981) . The protein components of the tight junction are beginning to be elucidated. The junctional adhesion molecules (JAMs) appear to be essential for tight junction assembly; monoclonal antibodies against JAMs inhibit junction formation following Ca 2 þ switch (Liu et al, 2000) . These transmembrane proteins associate as dimers in trans through their extracellular domains at sites of cell-cell contact and recruit intracellular scaffolding components to the tight junction (Kostrewa et al, 2001) . The intracellular domains of JAMs bind directly to the first PDZ domain of the cell polarity protein Par3/Asip/ Bazooka (Ebnet et al, 2001) . Par3 also associates with Par6, Cdc42, and aPKC (Joberty et al, 2000; Lin et al, 2000) all of which contribute to tight junction formation. The JAMs, as well as the tight-junction-localised proteins occludin and the claudins, also associate with the PDZ domains of the ZO family of scaffolding proteins (Furuse et al, 1993 (Furuse et al, , 1998 Fanning et al, 1998; Haskins et al, 1998 , Itoh et al, 1999 . aPKCs appear to be essential for the formation but not maintenance of tight junctions. MDCK cells expressing kinase-inactive aPKC mutants appear normal, however after Ca 2 þ depletion to disrupt cell-cell contacts, the localisation of the tight junction markers ZO-1, Par3, occludin, and claudin-1 is erratic following Ca 2 þ replacement ). These and other observations led to the hypothesis that aPKCs catalyse the transition of premature cellular junctions into differentiated asymmetric structures .
The aPKCs are activated by protein-protein interactions within the regulatory domains of the proteins. This serves the two purposes of destabilising the pseudosubstrate site interaction with the catalytic domain permitting binding/phosphorylation of substrate and tethering the kinase activity to specific regions of the cell (Moscat and Diaz-Meco, 2000) . PKCz and PKCl/i are homologous proteins that interact with Par6, a protein necessary for cellular asymmetry and asymmetric cell division. Interaction of aPKCs with Par6 restricts their localisation in the cell and activates their kinase activity (Joberty et al, 2000; Lin et al, 2000) .
In addition to the full-length aPKCs, there is also a PKCz isoform (PKMz) synthesised following transcription initiation of the PKCz gene from a brain-specific promoter located in an intron (Marshall et al, 2000) . This results in translation of an aPKC catalytic protein lacking the regulatory domain. The PKMz transcript is implicated in long-term potentiation, likely as a result of its constitutive kinase activity (Sacktor et al, 1993 , Osten et al, 1996 .
In this study, we describe the identification and characterisation of a distinct aPKC gene, designated PKCzII. This gene has a unique chromosomal localisation and is 98% identical with the cDNA encoding PKCz. An immunoreactive protein corresponding to PKCzII is detected in cultured cell lines and RNA can be detected in many mouse tissues. Amongst the 29 bp differences with PKCz, a deletion at nucleotide C1146 of PKCzII shifts the reading frame and results in truncation of the protein at amino acid 376. Therefore, PKCzII is composed of an aPKC regulatory domain without a functional catalytic domain. Recombinant PKCzII is partitioned in the nucleus, however its location changes when it interacts with proteins intrinsic to development of tight junctions. Expression of endogenous PKCzII in epithelial cells disrupts the assembly of tight junctions and promotes overgrowth of cells demonstrating its role in regulating aPKC-dependent functions.
Results

Cloning and identification of PKCfII
A stringent screen of a mouse genomic library (using the 5 0 end of the PKCz cDNA as a probe) identified three hybridising clones. The three clones were identical by restriction analysis and Southern blotting. Clone 3, containing a 13 kb insert, was selected for further analysis. Sequencing revealed this clone to contain a DNA sequence homologous with PKCz that was designated PKCzII (the genomic sequence has been annotated recently by the NCBI Annotation Project and is designated locus XM_124895). The genomic sequence of PKCzII was approximately 98% identical at the nucleotide level with the cDNA encoding 'authentic' murine PKCz (Figure 1 ) and retained a 3 0 UTR containing AATAAA poly A addition signal and a poly A stretch (data not shown). The PKCzII genomic sequence contains 29 nucleotide divergencies with respect to the PKCz cDNA sequence including deletion of nucleotides C1146, G1943, and a region flanking the PKCz stop codon (C1779-G1819).
Translation of the putative coding region of PKCzII demonstrates a high degree of identity at the protein level with PKCz ( Figure 2 ). The start codon of PKCz is conserved in PKCzII; however, the nucleotide deletion of C1146 in PKCzII results in a shift of the reading frame and termination of the putative coding region at nt1152 (Figure 1 ). Following translation, PKCzII would comprise a functional regulatory domain homologous with PKCz. The differences between PKCz and PKCzII in the catalytic region, however, are significant. In addition to loss of 60% of the catalytic domain, the shift in the PKCzII reading frame converts amino acid D356 to a threonine. This mutation ensures PKCzII lacks all catalytic activity since D356 is the catalytic base of PKCz responsible for stabilising the serine/threonine oxyanion of the substrate prior to transfer of the g phosphate from ATP (Protein Kinase Resource: www.sdsc.edu/kinases/). The frame shift also terminates the coding sequence in subdomain VIB (the catalytic loop) of the kinase domain suggesting that there is no catalytic function for this putative protein (see below).
Fluorescence in situ hybridisation (FISH) was performed to map the location of PKCz and PKCzII on mouse metaphase spreads stained with specific chromosome paints ( Figure 3A , A 0 ). Probes specific for PKCzII (X7; see Materials and methods) hybridised strongly to chromosome 7(A 2-3 region). PKCz-specific hybridising probes (pZ-X5; see Materials and methods) hybridised with chromosome 4(E 2 region). These locations were also confirmed by analysis of the Celera mouse genome database using the nucleotide sequences in Figure 1 (J Sgouros and S Parkinson, unpublished). Thus PKCzII has a unique chromosomal location on chromosome 7.
The data indicate that a PKCz-like gene on chromosome 7, lacking any introns, encodes a protein with an atypical PKC regulatory domain. To determine if this PKCz-homologous region is simply a nonexpressed pseudogene, Balb/c mouse RNA was extracted from various organs in order to assess PKCzII transcription by RT-PCR ( Figure 3B ). Since PKCzII genomic DNA contains no introns, extreme care was taken to ensure there was no DNA contamination of the extracted RNAs. Specific primers were designed that only amplified PKCz, PKMz, or PKCzII, as determined in control reactions. RNA encoding PKCz was detected primarily in muscle, heart, lung, kidney, and liver. PKMz RNA was abundant in the brain and could not be detected in other tissues. RNA derived from PKCzII was abundant in bone, lung, kidney, and liver, however it could be detected in most of the tissues tested. This demonstrates that PKCzII is transcribed from its locus on chromosome 7.
Next, we sought to address whether the RNA detected ( Figure 3B ) could be translated, generating this putative novel aPKC protein. In vitro transcription/translation of the open reading frame of the PKCzII genomic sequence identified the expected 45 kDa protein following autoradiography ( Figure 3C ). Detection was dependent on the ATG homologous to the PKCz open reading frame and, as expected, the T7-dependent product was disrupted by the presence of the 5 0 UTR. No product was detected from the 3 0 UTR only, demonstrating that the identified protein product derives from translation of the predicted open reading frame identified in Figure 2 . Expression and immunoprecipitation of PKCzII or PKCz as a positive control demonstrated conclusively that PKCzII had no intrinsic catalytic activity ( Figure 3D ).
In order to determine whether PKCzII was expressed in vivo, an antibody recognising the amino terminus of PKCz (kindly provided by Dr T Sacktor) was used to determine the expression of PKCzII in various cell lines. PKCzII and PKCz contain virtually identical N-termini. Therefore, detection of an immunoreactive 45 kDa band would indicate the presence of a PKCzII-related protein ( Figure 3E ). Various cell lines were grown to confluence, the number of cells determined and lysates analysed by Western blot using the N-terminal PKCz antibody or C-terminal aPKC antibody. A C-terminal antibody that does not distinguish between the aPKC subtypes (z/i/l) (71 kDa; Figure 3E , top panel) gave a signal following Western blot analysis of total cell lysates. NIH and U251 cells also gave a signal following longer exposure of the film. An N-terminal PKCz-specific antibody detected a 45 kDa band that comigrated with that detected in lysates from Cos7 cells transfected with a plasmid encoding PKCzII. Full-length PKCz could also be detected by the N-terminal antibody in these epithelial cell lines. This data support the conclusion that the PKCzII genomic locus on mouse chromosome 7A 2-3 encodes a new member of the aPKC family. An equivalent protein species is detected in human (293, Hela, MCF10A, MCF7), green monkey (Cos7), mouse (NIH3T3, HC11) and canine (MDCK)-derived cells suggesting PKCzII is expressed across mammalian species.
PKCfII interacts with Par6 and PKMf
To determine the potential for PKCzII to interact with candidate partners, we exploited the fact that ectopic expression of tagged PKCzII in COS7 cells produced an accumulation of the fusion protein in nuclei, such that the influence of coexpressed proteins could be investigated. Recombinant PKCzII and candidate binding partners were expressed in Cos7 cells tagged with the fluorescent proteins, CFP or YFP. YFP-PKCzII ( Figure 4A ; top left) was found primarily in the nucleus and could also be observed at cell contacts ( Figure 4A ; top left, arrow). This was in contrast to YFPPKMz ( Figure 4A ; bottom right) and YFP-PKCz (not shown), which were located almost exclusively in the cytoplasm.
PKCzII retains the regulatory domains predicted to be required for interaction with the aPKC catalytic domain (PKMz) and also with regulatory protein Par6.
Expressed alone, PKCzII and PKMz are located in nonoverlapping regions of the cell ( Figure 4A ). However, when CFP-PKCzII and YFP-PKMz were coexpressed in Cos7 cells, CFP-PKCzII was observed in the cytoplasm in proportion to the relative PKMz expression ( Figure 4B ). In high YFP-PKMzexpressing cells (single arrowhead) CFP-PKCzII was observed in the cytoplasm. In relatively low YFP-PKMz-expressing cells (double arrowhead) CFP-PKCzII still accumulated in the nucleus.
PKMz and full-length PKCz express identical catalytic domains. Despite the presence of its own regulatory domain, PKCz could also stabilise PKCzII in the cytoplasm although this required significantly higher expression levels for PKCz than those for PKMz (data not shown). These data suggest that the PKCz catalytic domain can interact with PKCzII.
Expressed alone, Par6c ( Figure 4A ; top right) could be detected in both the cytoplasm and nucleus of cells while, as noted above, PKCzII ( Figure 4A ; top left) was primarily nuclear. In low expressing CFP-Par6c cells, YFP-PKCzII retained its nuclear localisation (single arrowheads; Figure 4C ), however in high CFP-Par6c-expressing cells YFP-PKCzII resided in the cytoplasm ( Figure 4C ; double arrowhead) suggesting that Par6c interacts with PKCzII in vivo.
The effects on cellular localisation of PKCzII were also assessed by cell fractionation ( Figure 4D , E). Crude nuclear and cytoplasmic fractions were isolated from Cos7 cells expressing mycPKCzII, PKMz or mycPKCzII, and PKMz and the distribution of the expressed proteins was evaluated in the two fractions. Endogenous PKCl/i and exogenous PKMz were primarily cytoplasmic in the presence or absence of mycPKCzII. MycPKCzII was detected primarily in the nucleus when expressed alone in Cos7 cells. However, it appeared mainly in the cytoplasmic fraction when coexpressed with PKMz. This cell fractionation supports the fluorescent microscopy results presented in Figure 4B .
These data, exploiting the subcellular location observed on overexpression of PKCzII, indicate that PKCzII can interact with aPKCs and with aPKC regulatory proteins mutually regulating their cellular location. The pseudosubstrate site of PKCzII is a potential regulatory site that mediates interaction with the catalytic domain of the aPKCs. In addition, Par6 interacts with the N-terminal 120 amino acids of the aPKCs that includes the pseudosubstrate site. Interestingly, mutation of the PKCzII pseudosubstrate site (A119E) stabilises the protein in the cytoplasm ( Figure 4A ; bottom left). This indicates that the pseudosubstrate site determines the nuclear location of the overexpressed protein. To investigate this further, mycPKCzII or mycPKCzIIA119E was expressed in Cos7 cells with flagPar6c or PKMz and their association was examined following immunoprecipitation with the anti-myc 9E10 antibody ( Figure 4F ). The flagPar6c and PKMz detected in immunoprecipitates were specific for mycPKCzII-expressing cells. Notably, mutation of the mycPKCzII pseudosubstrate site (myczIIA119E) had no effect on the interaction between PKCzII and PKMz or flagPar6c (see Discussion) . This indicates that while the pseudosubstrate site contributes to nuclear localisation it is not required for binding to PKCz or Par6. It is likely however that PKCzII binding to these proteins blocks recognition of its pseudosubstrate site, leading to inefficient nuclear import.
PKCfII inhibits tight junction formation in mammary epithelial cells
PKCzII protein interacts with the cell polarity protein Par6 (Figure 4 ). This suggests that PKCzII could play a role in development of cellular junctions. It was previously reported that aPKC activity was required for the formation but not maintenance of tight junctions presumably via aPKC interaction with Par6 . PKCzII lacks any catalytic activity and could compete with aPKCs for binding to Par6 (Figure 4 ) inhibiting tight junction formation. Therefore, the role of endogenous PKCzII in the development of cell junctions was investigated using an RNAi approach. HC11 cells are a mouse mammary epithelial cell line endogenously expressing PKCzII ( Figure 3B ). They are normally maintained in an undifferentiated state in the presence of EGF and insulin. However, they form tight junctions and become differentiated in response to lactogenic hormones and produce b-casein and other differentiation markers (Stelwagen et al, 1999; Xie et al, 2002) . Preliminary experiments demonstrated that the selected RNAi sequence specifically inhibited expression of recombinant PKCzII but not PKCz in 293T cells (data not shown). HC11 cells were infected with an ecotropic retrovirus driving transcription of this RNAi molecule complementary and specific to PKCzII. RNA was extracted from HC11 cells infected with the PKCzII RNAi retrovirus (pSRII) or control virus (pSR), and the expression of PKCz, PKCzII, and b-actin was assessed by RT-PCR ( Figure 5A ). HC11 pSRII cells showed a significant loss of PKCzII message in all conditions tested while the detection of PKCz was unaffected demonstrating the specificity of the targeting sequence. The levels of expressed proteins were also assessed in the two cell lines ( Figure 5B ). Western blot analysis revealed a loss of the 45 kDa immunoreactive band (PKCzII) in pSRII cells while 6 cells was loaded on 12.5% PAGE gel, transferred to PVDF and incubated with an antibody directed against the C-terminus to detect fulllength aPKCs (l/i/z) (top panel) or an antibody directed against the N-terminus to detect PKCzII (bottom panel) (see Materials and methods for specificity). Lysate from Cos7 cells expressing a PKCzII cDNA plasmid (Cos7 (PKCzII)) is included as a migration control. no significant difference in the 70 kDa band (PKCz) was observed between pSR and pSRII HC11 lysates. These data demonstrate that the PKCzII gene identified here is expressed and further that PKCzII is translated from an mRNA distinct from PKCz.
Using the RNAi cell lines characterised in Figure 5A and B, we investigated the role of PKCzII in the development of cell polarity.
HC11 pSR and HC11 pSRII cells were seeded on coverslips, allowed to grow to confluence, fixed and stained for various junction markers ( Figure 5C ). Loss of PKCzII in pSRII cells correlated with the appearance of contiguous staining of ZO-1 in the apical plane. This contrasts with pSR cells where ZO-1 staining is punctate throughout the cytoplasm and disjointed at cell junctions. A similar pattern of behaviour was observed for the tight junction marker claudin-1 (data not shown). The b-actin staining was consistent with the ZO-1 localisation. Bundled cortical actin could be observed in the apical plane of pSRII but not pSR cells. The adherens junction marker b-catenin was located at cell-cell contacts in both cell lines suggesting that PKCzII did not regulate adherens junction formation. These results suggest that PKCzII specifically inhibits the development of tight junctions in HC11 cells.
In growth media containing EGF and insulin, HC11 cells adopt a transformed phenotype. They are characteristically rounded and grow in multiple layers losing contact inhibition 9) were lysed and the detergent-soluble fraction was incubated with Protein G Sepharose-coupled 9E10 (amyc) antibody. Detergent soluble (LOAD; bottom panels; 1:25 of total) and immunoprecipitates (mycIP; top panels) were run on 12.5% gels, transferred to PVDF and associated proteins were detected by probing with anti-aPKC C-terminal (PKMz), anti-flag (flagPar6c), or anti-myc (mycPKCzII/myczIIA119E) primary antibodies.
(pSR cells, Figure 5D ). However, in pSRII cells, loss of PKCzII correlates with a monolayer phenotype as demonstrated in Z stacks of cells stained with propidium iodide to label nuclei.
The loss of cell overgrowth (ie monolayer growth) can also be observed in orthogonal sections of cells stained with E-cadherin and b-catenin (Figure 6 ). The adherens junction . Following confluence, parallel cultures were switched to 2% serum for 24 h (serum) and then treated with prolactin/hydrocortisone (prolactin) for 72 h to induce differentiation (Xie et al, 2002) . Cells grown under these different conditions were harvested, RNA extracted, DNAse treated and the indicated message amplified with specific primers. For clarity, the images shown are negatives. Differentiation was confirmed by b-casein mRNA expression (not shown). DNA contamination was minimal as detected by the lack of amplification of b-actin in the absence of reverse transcriptase using the specified primers (b-actin -RT). (B) Western blot detection of PKCz and PKCzII in HC11 pSR (control) and HC11 pSRII (PKCzII RNAi) cells. HC11 pSR and pSRII cells were grown for 72 h postconfluence and the proteins extracted in lysis buffer. Lysates were run on 10% PAGE gels, transferred to PVDF membrane and immunoblotted with rabbit antibodies against the N-terminus of PKCz or the C-terminus of atypical PKCs. PKCzII is recognised by the N-terminal but not C-terminal antibody and is decreased in HC11 pSRII (PKCzII RNAi) versus pSR (control) cells. The asterisk denotes a nonspecific immunoreactive band. (C) Immunostaining of adherence and tight junction markers in HC11 pSR (control) and HC11 pSRII (PKCzII RNAi) cells. Cells were seeded on glass coverslips and grown to confluence in EGF, insulin, and 10% serum. marker localises to areas of cell-cell contact and multiple layers of cells can be observed. Blocking PKCzII expression repressed the transformed phenotype. HC11 pSRII cells stained with E-cadherin and b-catenin were essentially monolayer and contact inhibited ( Figure 6B) . In pSRII cells, the tight junction marker ZO-1 is located apically to the adherens junction markers E-cadherin and b-catenin and colocalises with the tight junction marker occludin ( Figure 6B ).
The data presented suggest that PKCzII interacts with Par6 and with the catalytic domain of aPKCs. Both interactions could potentially inhibit cell polarity and explain the formation of tight junctions in the absence of PKCzII expression. aPKC localisation was also modified in the pSRII cells ( Figure 6C ; note the junctional accumulation of aPKC) while the total aPKC activity in immunoprecipitates was not stimulated following PKCzII knockdown ( Figure 6D ). This data supports the hypothesis that PKCzII inhibits tight junction formation by preventing aPKC accumulation and activation at tight junctions.
Discussion
The data reported here introduce a new member of the murine aPKC family (PKCzII) and implicate it in regulating aPKC-dependent cellular processes. The murine gene encoding this protein has a unique chromosome location and retains a high degree of identity with the PKCz cDNA sequence. The synthesised protein has 98% amino acid identity to the regulatory domain of PKCz but lacks any catalytic function. Despite lacking catalytic activity, domains for interaction with regulatory proteins are retained (Lin et al, 2000; Suzuki et al, 2001) . It is shown that PKCzII interacts with Par6c (Figure 4) , an aPKC-binding protein required for tight junction formation, and so prevents tight junction formation (Figures 5, 6 ). Thus in vivo, PKCzII functions to control aPKC signalling pathways contributing to cell polarity. The knockdown of PKCzII protein using an RNAi approach in HC11 epithelial cells demonstrates that this aPKC homolog inhibits tight junction formation. Previous studies have identified an essential role for aPKC activity in establishing tight junction formation . The N-terminus of Par6 contains an aPKC-binding motif that recognises the regulatory domain of the kinase. Cdc42 binds to Par6 through its CRIB and PDZ domains and activates aPKC kinase activity (Garrard et al, 2003) . The Par6/aPKC complex also interacts with the scaffolding protein Par3 permitting its phosphorylation; an event correlated with development of tight junctions (Hirose et al, 2002) . In the absence of any effect on aPKC activity it is concluded that PKCzII competes for recruitment to cell junctions. This may be direct competition with Par6 or the Par6/PKCzII complex may compete with Par6/aPKC for activated Cdc42 preventing phosphorylation of Par3 and/or recruitment of other complexes required for development of tight junctions. Other factors may also contribute to the phenotype observed in Figures 5 and 6 including the possibility that PKCzII interacts with the catalytic domain of aPKCs (see Figure 4) .
The data presented are consistent with a previous study that determined a PKCz regulatory fragment inhibited tight junction formation in mammalian epithelial cells (Gao et al, 2002) . In this study, a synthetic recombinant N-terminal fragment consisting of the first 126 amino acids of PKCz lacking kinase activity delayed the development of mature tight junctions. This was dependent on its interaction with Par6 since mutation of the PKCz Par6-binding site abrogated the delay in the recruitment of ZO-1 to tight junctions. This data support the idea that PKCzII inhibits development of the Cdc42-Par6-aPKC complex although it is unclear whether the Par6-binding mutant used by Gao et al. (2002) still interacts with aPKC catalytic domains. In addition, a PKCl mutation identified from a genetic screen in zebrafish was found to be responsible for the heart-and-soul (has) phenotype in which the animals demonstrate a loss of normal heart, kidney, and retinal patterning (Horne-Badovinac et al, 2001; Peterson et al, 2001) . The has phenotype results from premature termination of the PKCl coding sequence. The has mutants identified lack the C-terminal 69 and 73 amino acids and completely lack any catalytic activity.
The Ca 2 þ switch assay is routinely used to investigate formation of cellular junctions. Depletion of extracellular Ca 2 þ disrupts cell-cell contacts and addition of extracellular Ca 2 þ permits junctions to form. Using this assay, previous reports demonstrated that the formation of tight junctions is dependent on aPKC activity since kinase-dead mutants disrupt their formation . Supporting these findings, MDCK cells overexpressing PKCzII over grow each other forming multiple layers and have disrupted ZO-1 localisation following Ca 2 þ switch (data not shown). This observation is consistent with the HC11 data, however PKCzII is poorly expressed in transfected epithelial cells complicating analysis through ectopic expression. The presence of the PKCzII gene in mice likely represents a reverse transcriptase-dependent insertion of the PKCz cDNA into the genome since the PKCzII genomic sequence retains a high degree of homology but lacks any introns. Spontaneous mutation of the inserted sequence resulted in the deletion of nucleic acid 1146 and synthesis of a PKCz regulatory domain lacking catalytic function. There are several reports of similar insertions occurring in the mammalian genome however most of these events result in nonfunctional genomic sequences referred to as pseudogenes. From the data presented it appears that PKCzII was inserted into a region that permits transcription of its sequence resulting in a stable mRNA and 45 kDa protein.
Part of the analysis of the PKCzII-Par6c interaction in vivo exploited the distinct subcellular compartmentation of the proteins. In Cos7 cells PKCzII and a homologous fragment of PKCz (not shown) are primarily localised in the nucleus of cells, suggesting the presence of a nuclear localisation signal (NLS) in the protein. These observations support previous studies identifying an NLS within the regulatory domain of full-length aPKCs (Perander et al, 2001) . A pseudosubstrate site PKCzII mutant is cytoplasmic suggesting this region plays a role in nuclear retention or targeting. In contrast, an homologous pseudosubstrate site mutation in PKCl/i stabilises the protein in the nucleus (Perander et al, 2001) . Differences in the nuclear trafficking of PKCl/i and PKCz have been reported previously. Significantly, identical mutants deleting the N-terminus up to and including the pseudosubstrate site had completely opposite cellular locations; the PKCz mutant was cytoplasmic while the PKCl mutant was nuclear (Perander et al, 2001) . The location of the N-terminal mutant of PKCz (Perander et al, 2001) , PKMz, PKCzII, and PKCzIIA119E (this study) are all consistent and demonstrate a contribution of the pseudosubstrate site to nuclear localisation of PKCz. For PKCl/i, there may be an additional NLS located C-terminal to the pseudosubstrate site that is exposed upon pseudosubstrate site release from the catalytic domain.
The presence of PKCzII in the cytoplasm following mutation of A119E correlates with the location of PKCzII in vivo when it is in a complex with Par6c or PKMz. Therefore, PKCzII interaction with Par6c or PKMz likely masks the NLS, of which the pseudosubstrate site appears to be a part. Furthermore, recombinant Par6c is also partially located in the nucleus when expressed on its own, however, in the presence of PKCz or PKCzII it is primarily cytoplasmic suggesting that the interaction either masks an NLS in Par6c or exposes a nuclear export signal somewhere in the complex. In differentiated epithelial cells, Par6 has only been detected at cell junctions. This may be due to its interaction with aPKC and other proteins that limit its localisation; the distribution of endogenous Par6 in other cell types and under various conditions may be varied. The observation that recombinant Par6c is entirely cytoplasmic when coexpressed with interacting proteins but only partially in their absence suggests this might be the case and needs to be investigated further.
Synthesis of truncated proteins that regulate cellular functions is a common theme in signal transduction. Translation of these inhibitory proteins can occur from alternate splicing of mRNAs or from distinct genes with unique chromosomal locations. Synthesis of the focal adhesion kinase (FAK)-related protein FRNK is an example of regulation by alternate splicing of a single mRNA (Schaller et al, 1993) . Reminiscent of PKCzII and PKCz, FRNK is composed of the C-terminal regulatory domain of FAK but lacks any kinase activity. Another example is the soluble frizzled-related proteins (sFRPs). The sFRPs are located on distinct genes that are homologous to the frizzled receptors for the Wnts. These secreted proteins are homologous to the cysteine-rich domain (CRD) of the frizzled 7-transmembrane receptors and inhibit Wnt-dependent signalling pathways leading to stabilisation of b-catenin in the cytoplasm (Rattner et al, 1997) .
Interestingly, it appears that PKCz signalling pathways are also regulated by multiple strategies. PKMz is synthesised from the PKCz gene on mouse chromosome 4. It lacks most of the regulatory domain and likely constitutively phosphorylates substrates due to lack of an inherent pseudosubstrate site. PKCzII, however, lacks all catalytic activity but can interact with regulatory proteins preventing aPKC-dependent signalling. All of the aPKC members likely contribute to form an integrated cellular response to each stimulus.
In conclusion, PKCzII is identified as a new member of the aPKC family. It serves as an endogenous inhibitor of aPKC functions through interaction with known regulatory proteins. As a result of these properties, PKCzII prevents tight junction formation in epithelial cells.
Materials and methods
Reagents
Antibodies. The following antibodies were used: rabbit anti-aPKC C-terminal antibody (Santa Cruz) detects PKCl/i and PKCz (data not shown), rabbit anti-PKCz N-terminal antibody (generously provided by Dr T Sacktor) is specific for PKCz and does not crossreact with PKCl/i, mouse M2 anti-flag (Sigma), rabbit anti-ZO-1 (Zymed), mouse fitc-conjugated anti-occludin (Zymed), tritcconjugated phalloidin (Molecular Probes), mouse fitc-conjugated E-cadherin (BD Transduction Labs), mouse anti-b-catenin (BD Transduction Labs), Cy3-conjugated anti-mouse (Jackson ImmunoResearch Laboratories), FITC-conjugated anti-rabbit (Dako).
Plasmids. PKCzII was amplified from mouse brain DNA using the following primers; zetaII24( þ ) (5 0 -AAGCTTTGGCGGAGTGCGC-CATG-3 0 ) and zetaII2133(À) (5 0 -GGTACCAGA-CATCATCGGTACAC-3 0 ). The resulting 2 kb band was ligated into PCR Blunt (Invitrogen), excised with HindIII and KpnI and ligated into pDNA3.1(Hygro þ ) (Invitrogen). PcDNA3.1-PKCz (rat) was made by subcloning PKCz into pcDNA3.1-PKCzII cut with NotI/XbaI. PcDNA3.1-PKMz was made by subcloning in the RT-PCR product (see RT-PCR below) cut with SpeI/ClaI (500 bp fragment) into pcDNA3.1-PKCz cut with NheI/ClaI. PEYFP-PKMz was constructed by cutting pcDNA3. 1-PKCz with NdeI/PmeI, blunting the ends with Vent polymerase and ligating the 1.2 kb fragment into pEYFP-C1 (Clontech) cut with SmaI. The amino acid sequence of PKMz was predicted from the sequence of RT-PCR products using PKMz-specific primers and RNA from mouse brain (see below). PcDNA3.1-mycPKCzII was generated by partial digestion of pcDNA3.1-PKCzII with NheI/ NgoMIV and ligation of oligos encoding the myc epitope. PEYFPPKCz was constructed by cutting pEYFP-PKMz with BspE1/EcoRV and ligating in a fragment from pcDNA3.1-PKCz cut with NgoMIV/ EcoRV. PECFP-PKCz was constructed by subcloning pEYFP-PKCz into the pECFP-C1 vector (Clontech). PEYFP-PKCzII was constructed by cutting pEYFP-PKCz with BstEII/BamHI and ligating in the equivalent fragment from pcDNA3.1-PKCzII. PECFP-PKCzII was constructed by subcloning into the pECFP vector. Flag-tagged Par6c (pFlagPar6c) was a gift from Dr Dan Lin and Dr Tony Pawson. To create pECFP-Par6c and pEYFP-Par6c the pFlagPar6c cDNA was cut with EcoRI/PvuII and ligated into pECFP-C1 and pEYFP-C1 cut with EcoRI/SmaI. The PKCzIIA119E mutation was generated by PCR using pcDNA3.1-PKCzII as the template and the primers; 5 0 -CTACCGCCATGGAGAAAG-AAGATGGAGAAAGCCG-3 0 and zetaII-2133(À) (described above). The product was cut with NcoI/ClaI and ligated into pcDNA3.1-mycPKCzII to make pcDNA3.1-mycPKCzIIA119E. All DNA constructs were confirmed by sequencing. The PKCzII sequence obtained correlated with the sequence established by Celera for the mouse genome (J Sgouros and S Parkinson, unpublished).
Tissue culture. Cos7, MDCK, HELA, 293, NIH3T3, U251, and Caco2 cells were maintained in DMEM containing 10% FBS and penicillin/ streptomycin. MCF10A cells were grown in DMEM containing Ham's F12, 5% horse serum, 10 mg/ml insulin, 5 mg/ml hydrocortisone, 20 ng/ml EGF, 100 ng/ml cholera toxin, and penicillin/ streptomycin. HC11 cells were maintained in RPMI, 10% FBS, penicillin/streptomycin, 10 mg/ml insulin, and 20 ng/ml EGF.
Virus production. Retrovirus expressing an RNAi against PKCzII were developed using the pSuppressorRetro (pSR) system (Imgenex, San Diego). Complementary oligos (PKCzII target sequence: 5 0 -aagcatgtatttgagcaggcg-3 0 ) were ligated into pSR, checked by sequencing, and cotransfected into 293T cells with the packaging vector pCL-Eco. Control virus was generated against PKCz and a sealed pSR plasmid cotransfected with the packaging vector. Virus was collected 48 h post-transfection, filtered, added to HC11 cells and stable lines selected with neomycin. Under growth culture conditions (above), only the PKCzII viral-infected lines demonstrated the change in phenotype; the other cell lines were indistinguishable from noninfected cells. However, in other culture conditions, virus targetting PKCz demonstrated a significant phenotype distinct from PKCzII. To avoid confusion concerning these cell lines, the 'vector only' line of pSR is shown as a control.
Cloning and chromosome localisation of murPKCzII. Using a randomly labelled ([g-32 P]-dCTP) 300 bp 5 0 fragment of PKCz cDNA as a probe, a mouse genomic l gt 10 phage library was screened. Three identical hybridising clones were isolated after primary screening and purified by two further rounds of selection. Clone 3, containing a 13 kb insert (flanking PKCzII), was selected for further analysis. The chromosome localisation of PKCzII was assessed by FISH using the following probes and chromosomal paints on mouse metaphase spreads, X7 (PKCzII 3 0 UTR), pZ-X5 (PKCz intron sequence).
Alignments. Alignments were performed using Clustal X software with the sequences encoding mouse PKCzII and PKCz (accession number M94632).
In vitro transcription/translation. In total, 1 mg of genomic PKCzII DNA composed of 5 0 UTR (2.5 kb), putative PKCzII coding region (1.8 kb) and 3 0 UTR (8.7 kb) was transcribed in vitro and translated in rabbit reticulocyte lysates (Promega) according to manufacturers instructions at 301C for 2 h in the presence of 35 S-methionine. The entire reaction was denatured in sample buffer, separated on a 10% acrylamide gel and analysed by autoradiography.
RT-PCR. Mouse tissue total RNA was extracted using Trizol reagent (Gibco) followed by extensive treatment of the RNA fraction with DNAse. Reverse transcription was carried out using the Access RT-PCR system (Promega) with the following changes to the manufacturers protocol. Reverse transciption was performed using random 9-mers as primers. RNA was ensured to be DNA-free if b-actin was amplified using musBactI (5 0 -tgacggggtcacccacac tgtgccc-atcta-3 0 ) and musBactII (5 0 -agtaacagtccgcctagaagcacttgcggt-3 0 ) in the presence but not absence of reverse transcriptase. The following primers were used for amplification by RT-PCR and were specific for their designated targets as confirmed by sequencing: PKCz-(zeta199( þ ) 5 0 -tgggtggacagtgaaggtgac-3 0 , zeta392(À) 5 0 -gtt ggctcggtacagcttc-3 0 ), PKCzII-(zeta199( þ ), zetaII390(À) 5 0 -attggctcggtac-ggcttt-3 0 ), PKMz-(psizeta( þ ) 5 0 -ggagacccacccagcccattg-3 0 , zeta392(À)). Transfections. Cos7 cells (1.5 Â10 5 ) were seeded into 3 cm dishes, left overnight, and transfected by CaPO 4 with 1 mg of DNA. The following day the precipitate was removed, cells washed and left to recover overnight.
Immunoprecipitations. Cells (10 cm dish) were lysed in 1 ml buffer containing 25 mM HEPES (pH 7.4), 150 mM NaCl, 1% NP-40, 0.5 mM EDTA, 5 mM MgCl 2 , 2 mM DTT, 1 mM PMSF, and complete protease inhibitor cocktail tablet (Boehringer Mannheim). The lysate was collected by scraping and insoluble material removed by centrifugation (100 000 g, 30 min) . Protein G-coupled antibody was added to the soluble lysate and rotated for 2-3 h at 41C. Immunocomplexes were washed 4 Â with lysis buffer and solubilised for gel electrophoresis in 100 ml of sample buffer.
Immunocomplex activity determination. Immunoprecipitates of PKCz or myc-tagged PKCz and PKCzII were isolated essentially as above except in the presence of 1 mM okadaic acid, 50 mM sodium fluoride, 10 mM p-nitrophenylphosphate, 10 mM sodium orthovanadate and in the absence of MgCl 2 . Immunocomplexes on protein G-Sepharose beads were incubated with shaking at 221C in the presence of 50 mM HEPES pH 7.5, 10 mM [g-32 P]ATP, 10 mM MgCl 2 , 1 mg/ml myelin basic protein and 1 mM okadaic acid. After 15 min the reaction was stopped by the addition of sample buffer. Radiolabelled myelin basic protein was separated on a 12.5% polyacrylamide gel, identified by autoradiography, and quantified by direct Cerenkov counting.
Fractionation. Cos7 cells were lysed with 1 ml (41C) hypotonic buffer (10 ml Tris (pH 8.0), 10 mM NaCl, 3mM MgCl 2 , 0.25% NP-40)/10 cm 2 dish. Cells were scraped into Eppendorf tubes and passed 4 Â through a 21 gauge needle. The lysate was spun for 6 s at 12 000 rpm at 41C to isolate nuclei. The cytosolic fraction was removed and proteins precipitated with TCA. The nuclear-and cytosolic-rich fractions were resuspended in equal volumes of sample buffer and analysed by electrophoresis and Western blot.
Immunofluorescence and confocal microscopy. Live cell and fixed cell microscopy was performed on an inverted confocal laser scanning microscope (Carl Zeiss, Inc.) equipped with an 63X/ 1.4Plan-Apochromat oil-immersion objective and fitted with an environmental chamber. Each image represents a single twodimensional projection. For live cell microscopy, cells were seeded on 35 mm glass bottom dishes (MatTek Corporation), and transfected with the indicated plamids the following day. Alternatively, cells were fixed on 1.5 mm coverslips with 100% MeOH (À20 o C) for 10 min, and blocked in Tris-buffered saline 0.1% Triton (TBST) with 3% BSA (30% stock, Sigma) for 30 min. Primary antibodies were added in TBST 3% BSA overnight at 41C. Cells were washed, then fluorescent-conjugated secondary antibody (see reagents) added (1:200 in TBST) for 30 min. Cells were washed in TBST, TBS, and H 2 O, then mounted in Mowiol Mount (Sigma) containing DABCO (Sigma).
